A stock’s 52-week high and low prices can offer a wealth of information about its current standing and prospective future performance. Avalo Therapeutics Inc’s current trading price is -60.94% away from its 52-week high, while its distance from the 52-week low is 84.37%. The stock’s price range for this time frame has been between $3.39 and $16.00. The trading volume of the company’s shares in the Healthcare reached around 0.8 million for the day, which was evidently higher than the average daily volume of 82780.0 over the last three months.
Avalo Therapeutics Inc (AVTX) currently has a stock price of $6.25. The stock saw a sharp increase in the last trading session, hitting a high of $48.0 after opening at $6.25. The lowest recorded price for the day was $15.0 before it closed at $5.66.
Avalo Therapeutics Inc’s stock has seen a rocky market performance. The company’s stock achieved a 1-year high of $16.00 on 10/28/24, and the lowest price during that time was $3.39, recorded on 05/14/25.
How Financial Performance Impacts Market Capitalization
Avalo Therapeutics Inc (AVTX) has experienced a quarterly rise of 34.99% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 67.67M and boasts a workforce of 23 employees.
Decoding Analysts’ Ratings for Avalo Therapeutics Inc
As of right now, 6 analysts are rating Avalo Therapeutics Inc as a BUY, 2 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.45, with a change in price of -1.85. Similarly, Avalo Therapeutics Inc recorded 90,714 in trading volume during the last 100 days, posting a change of -22.84%.
How AVTX’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for AVTX stands at 0.02. Similarly, the long-term debt-to-equity ratio is also 0.02.
AVTX Stock Stochastic Average
Avalo Therapeutics Inc’s raw stochastic average for the past 50 days is currently at 91.96%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 87.50%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 81.03% and 72.73%, respectively.
AVTX Stock Price Performance Analysis
A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. Year to date metric has recorded a loss of -50.00%.However, over the last six months, we can see a stronger performance of -1.11%. Over the last 30 days, the price of AVTX has fallen by 39.82%. And in the last five days, it has surged by 30.75%.
